Regulation of Apoptosis in Activated Primary T cells
Regulation of Apoptosis in Activated Primary T cells
批准号:
7242520
负责人:
David A Hildeman
金额:
$35.32万
依托单位国家:
美国
项目类别:
财政年份:
2005
资助国家:
美国
项目状态:
已结题
起止时间:
2005-06-01 至 2008-08-31
关键词:
AffectAllelesAntigensApoptosisApoptoticAutoimmune DiseasesAutoimmunityAutomobile DrivingBiological MetamorphosisCD8B1 geneCell CountCell SurvivalCellsCessation of lifeCharacteristicsComplementDataDependenceDisadvantagedDisruptionEquilibriumGenerationsGoalsGraft RejectionHomeostasisImmune systemImmunityIn VitroInfectionInterleukin-7LeftLymphoidMaintenanceMediatingMemoryModelingMolecularMolecular TargetMusNeoplasmsNumbersPathway interactionsPeripheralPhasePhenotypePopulationPopulation ControlProcessProteinsRegulationResearchResearch PersonnelRoleSideSignal TransductionStagingT memory cellT-LymphocyteTestingTherapeuticTimeVaccinationViralVirusWorkalpha chain interleukin-7 receptorimprovedin vivolong term memorypreventprogramsterminally differentiated effector memory (TEM) T cellsthymocyte
中文摘要
描述(由申请人提供):T细胞稳态的维持对于适应性免疫系统的正常功能至关重要。虽然T细胞稳态最终是通过维持不同的T细胞群体(幼稚、效应、记忆)来实现的,但在每个群体中维持稳态的机制尚不清楚。虽然IL-7在这些阶段中的每一个对于T细胞在体内的存活是至关重要的,但是对于控制不同T细胞群体的稳态的下游存活机制知之甚少。我们的初步数据表明,抗凋亡分子Bim及其抗凋亡拮抗剂Bcl-2调节T细胞稳态,至少部分通过改变T细胞在不同人群中的存活。Bcl-2对于幼稚T细胞存活是至关重要的,至少部分地抵消Bim的促凋亡作用。在病毒特异性效应T细胞中,大多数病毒特异性T细胞上的IL-7 Ra和Bcl-2水平降低,使它们对Bim的促凋亡作用敏感。在缺乏Bim的情况下,特定类型的病毒特异性记忆T细胞的数量在功能上和表型上都增加。这些数据表明Bim的作用是限制可以进入记忆区的效应T细胞的数量。然而,并非所有的记忆T细胞都受到影响,记忆T细胞的长期存活可能不需要Bim或Bcl-2。总之,这些数据表明,在宿主内的T细胞的独立群体的维持是由它们对凋亡/存活分子的不同依赖性控制的。该提议的中心假设是,从幼稚T隔室到记忆T隔室的进展涉及对Bim和Bcl-2之间的动态平衡的阶段特异性依赖,该平衡影响幼稚T细胞、效应T细胞和效应记忆T细胞的IL-7依赖性存活,但不影响中央记忆T细胞。该项目的目的是确定Bim和Bcl-2在以下方面的作用:1.幼稚T细胞稳态; 2.效应T细胞凋亡; 3.记忆T细胞存活和表型。这项研究的长期目标是确定可用于治疗的分子靶点,以提高T细胞存活率(即改善疫苗接种)或降低T细胞存活率(即抑制自身免疫性疾病或移植排斥)。
英文摘要
DESCRIPTION (provided by applicant): Maintenance of T cell homeostasis is critical for normal functioning of the adaptive immune system. Although T cell homeostasis is ultimately achieved through maintenance of distinct T cell populations (naive, effector, memory), the mechanisms by which homeostasis is maintained in each population is unclear. Although IL-7 is critical for survival of T cells in vivo at each of these stages, little is known about the downstream survival mechanisms by which homeostasis of distinct T cell populations are controlled. Our preliminary data indicate that the anti-apoptotic molecule, Bim and its anti-apoptotic antagonist, Bcl-2, regulate T cell homeostasis, at least in part by altering T cell survival in distinct populations. Bcl-2 is critical for naive T cell survival, at least in part, to counteract the pro-apoptotic effects of Bim. In viral-specific effector T cells, levels of IL-7Ralpha and Bcl-2 are decreased on most viral-specific T cells, leaving them susceptible to the pro-apoptotic effects of Bim. In the absence of Bim the numbers of a particular type of viral-specific memory T cell are increased, both functionally and phenotypically. These data suggest that the role of Bim is to limit the numbers of effector T cells that can enter the memory compartment. However, not all memory T cells are affected and the long-term survival of memory T cells may not require Bim or Bcl-2. Taken together, these data suggest that the maintenance of independent populations of T cells within the host is controlled by their different dependence on apoptosis/survival molecules. The central hypothesis of this proposal is that progression from naive to memory T compartments Involves stage-specific dependence on a dynamic balance between Bim and Bcl-2, a balance that affects IL-7-dependent survival of naive, effector, and effector memory but not central memory T cells. The aims of the project are to determine the roles of Bim and Bcl-2 in : 1. naive T cell homeostasis; 2. effector T cell apoptosis; 3. memory T cell survival and phenotype. The long-term goal of this research is to identify molecular targets that could be exploited therapeutically to enhance T cell survival (i.e. to improve vaccination) or to decrease T cell survival (i.e. suppress autoimmune disease or transplant rejection).
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Pathogenesis and therapeutic targeting of immune disorders
-
批准号:9308845
-
项目类别:
-
资助金额:$14.21万
-
财政年份:2016
-
负责人:David A Hildeman
-
依托单位:
Pathogenesis and therapeutic targeting of immune disorders
-
批准号:9925180
-
项目类别:
-
资助金额:$13.15万
-
财政年份:2016
-
负责人:David A Hildeman
-
依托单位:
Pathogenesis and therapeutic targeting of immune disorders
-
批准号:9149365
-
项目类别:
-
资助金额:$14.06万
-
财政年份:2016
-
负责人:David A Hildeman
-
依托单位:
Exploiting the DNA damage response to selectively sculpt the T cellrepertoire
-
批准号:9054073
-
项目类别:
-
资助金额:$39.0万
-
财政年份:2014
-
负责人:David A Hildeman
-
依托单位:
Exploiting the DNA damage response to selectively sculpt the T cellrepertoire
-
批准号:8780156
-
项目类别:
-
资助金额:$39.0万
-
财政年份:2014
-
负责人:David A Hildeman
-
依托单位:
Exploiting the DNA damage response to selectively sculpt the T cellrepertoire
-
批准号:9248785
-
项目类别:
-
资助金额:$39.0万
-
财政年份:2014
-
负责人:David A Hildeman
-
依托单位:
Control of Diabetes by Manipulation of Bc12 Family Members
-
批准号:8130455
-
项目类别:
-
资助金额:$38.25万
-
财政年份:2011
-
负责人:David A Hildeman
-
依托单位:
Control of Diabetes by Manipulation of Bc12 Family Members
-
批准号:8502469
-
项目类别:
-
资助金额:$32.11万
-
财政年份:2011
-
负责人:David A Hildeman
-
依托单位:
Control of Diabetes by Manipulation of Bc12 Family Members
-
批准号:8690027
-
项目类别:
-
资助金额:$33.28万
-
财政年份:2011
-
负责人:David A Hildeman
-
依托单位:
Control of Diabetes by Manipulation of Bc12 Family Members
-
批准号:8294697
-
项目类别:
-
资助金额:$33.28万
-
财政年份:2011
-
负责人:David A Hildeman
-
依托单位:
Regulation of Apoptosis in Activated Primary T Cells
-
批准号:8079306
-
项目类别:
-
资助金额:$10.23万
-
财政年份:2010
-
负责人:David A Hildeman
-
依托单位:
Regulation of Apoptosis in Activated Primary T Cells
-
批准号:8389656
-
项目类别:
-
资助金额:$34.78万
-
财政年份:2005
-
负责人:David A Hildeman
-
依托单位:
Regulation of Apoptosis in Activated Primary T cells
-
批准号:6983776
-
项目类别:
-
资助金额:$36.76万
-
财政年份:2005
-
负责人:David A Hildeman
-
依托单位:
Regulation of Apoptosis in Activated Primary T cells
-
批准号:7071090
-
项目类别:
-
资助金额:$36.37万
-
财政年份:2005
-
负责人:David A Hildeman
-
依托单位:
Regulation of Apoptosis in Activated Primary T Cells
-
批准号:8197073
-
项目类别:
-
资助金额:$36.99万
-
财政年份:2005
-
负责人:David A Hildeman
-
依托单位:
Regulation of Apoptosis in Activated Primary T Cells
-
批准号:7743075
-
项目类别:
-
资助金额:$37.55万
-
财政年份:2005
-
负责人:David A Hildeman
-
依托单位:
IL-1 dependent anorexia during CNS viral infection
-
批准号:7039268
-
项目类别:
-
资助金额:$16.84万
-
财政年份:2005
-
负责人:David A Hildeman
-
依托单位:
IL-1 dependent anorexia during CNS viral infection
-
批准号:7318492
-
项目类别:
-
资助金额:$16.39万
-
财政年份:2005
-
负责人:David A Hildeman
-
依托单位:
Regulation of Apoptosis in Activated Primary T Cells
-
批准号:7581426
-
项目类别:
-
资助金额:$10.65万
-
财政年份:2005
-
负责人:David A Hildeman
-
依托单位:
Regulation of Apoptosis in Activated Primary T Cells
-
批准号:7990436
-
项目类别:
-
资助金额:$36.99万
-
财政年份:2005
-
负责人:David A Hildeman
-
依托单位:
海外基金